Continuous glucose monitoring in cystic fibrosis – A practical guide

Christine L. Chan; Katie Larson Ode; Andrea Granados; Amir Moheet; Antoinette Moran; Shihab Hameed

doi:10.1016/j.jcf.2019.08.025

Continuous glucose monitoring in cystic fibrosis – A practical guide

Christine L. Chan, Katie Larson Ode, Andrea Granados, Amir Moheet, Antoinette Moran, Shihab Hameed

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Our ability to monitor blood glucose levels has become increasingly accurate over the last few decades. Continuous glucose monitoring (CGM) technology now allows providers and patients the ability to monitor glucose levels retrospectively as well as in real-time for diabetes management. CGM also provides the ability to study glucose patterns and trends for insight into the pathophysiology and natural history of disease. CGM captures a more complete picture of glucose profiles than traditional measures of glycemia such as the hemoglobin A1c or self-monitoring of blood glucose levels. This article provides a review of the history of glucose monitoring, a review of the literature pertaining to CGM with a focus on studies in patients with cystic fibrosis, and discusses practical uses of CGM technology and its application for the evaluation and management of cystic fibrosis related diabetes.

Original language	English (US)
Pages (from-to)	S25-S31
Journal	Journal of Cystic Fibrosis
Volume	18
DOIs	https://doi.org/10.1016/j.jcf.2019.08.025
State	Published - Oct 2019

Bibliographical note

Funding Information:
CLC, KLO, AG, AM, and AM receive grant support through the Cystic Fibrosis Foundation, Emerging Leaders in CF Endocrinology (EnVision) Program. Additionally, CLC is supported by the Cystic Fibrosis Foundation grant CHAN16A0 and receives industry support from Insulet and Dexcom . AG is supported by Washington University Institute of Clinical & Translational Sciences ( ICTS ) KL2 Career Development Awards Program KL2TR002346-02 . SH is grateful for funding assistance from the National Health and Medical Research Council of Australia , the Australasian Cystic Fibrosis Research Trust , Regional Diabetes Support Scheme , Sydney Children's Hospital Foundation , Australasian Pediatric Endocrine Care Grant from Pfizer , and for Industry support from Novo Nordisk , Medtronic , Abbott Diagnostics .

Publisher Copyright:
© 2019 European Cystic Fibrosis Society

Keywords

Artificial pancreas
Continuous glucose monitoring
Cystic fibrosis related diabetes

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.jcf.2019.08.025

Find It

Find It at U of M Libraries

Cite this

@article{4b40d736348147db871d11bbde284f9c,

title = "Continuous glucose monitoring in cystic fibrosis – A practical guide",

abstract = "Our ability to monitor blood glucose levels has become increasingly accurate over the last few decades. Continuous glucose monitoring (CGM) technology now allows providers and patients the ability to monitor glucose levels retrospectively as well as in real-time for diabetes management. CGM also provides the ability to study glucose patterns and trends for insight into the pathophysiology and natural history of disease. CGM captures a more complete picture of glucose profiles than traditional measures of glycemia such as the hemoglobin A1c or self-monitoring of blood glucose levels. This article provides a review of the history of glucose monitoring, a review of the literature pertaining to CGM with a focus on studies in patients with cystic fibrosis, and discusses practical uses of CGM technology and its application for the evaluation and management of cystic fibrosis related diabetes.",

keywords = "Artificial pancreas, Continuous glucose monitoring, Cystic fibrosis related diabetes",

author = "Chan, {Christine L.} and Ode, {Katie Larson} and Andrea Granados and Amir Moheet and Antoinette Moran and Shihab Hameed",

note = "Funding Information: CLC, KLO, AG, AM, and AM receive grant support through the Cystic Fibrosis Foundation, Emerging Leaders in CF Endocrinology (EnVision) Program. Additionally, CLC is supported by the Cystic Fibrosis Foundation grant CHAN16A0 and receives industry support from Insulet and Dexcom . AG is supported by Washington University Institute of Clinical & Translational Sciences ( ICTS ) KL2 Career Development Awards Program KL2TR002346-02 . SH is grateful for funding assistance from the National Health and Medical Research Council of Australia , the Australasian Cystic Fibrosis Research Trust , Regional Diabetes Support Scheme , Sydney Children's Hospital Foundation , Australasian Pediatric Endocrine Care Grant from Pfizer , and for Industry support from Novo Nordisk , Medtronic , Abbott Diagnostics . Publisher Copyright: {\textcopyright} 2019 European Cystic Fibrosis Society",

year = "2019",

month = oct,

doi = "10.1016/j.jcf.2019.08.025",

language = "English (US)",

volume = "18",

pages = "S25--S31",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier",

}

TY - JOUR

T1 - Continuous glucose monitoring in cystic fibrosis – A practical guide

AU - Chan, Christine L.

AU - Ode, Katie Larson

AU - Granados, Andrea

AU - Moheet, Amir

AU - Moran, Antoinette

AU - Hameed, Shihab

N1 - Funding Information: CLC, KLO, AG, AM, and AM receive grant support through the Cystic Fibrosis Foundation, Emerging Leaders in CF Endocrinology (EnVision) Program. Additionally, CLC is supported by the Cystic Fibrosis Foundation grant CHAN16A0 and receives industry support from Insulet and Dexcom . AG is supported by Washington University Institute of Clinical & Translational Sciences ( ICTS ) KL2 Career Development Awards Program KL2TR002346-02 . SH is grateful for funding assistance from the National Health and Medical Research Council of Australia , the Australasian Cystic Fibrosis Research Trust , Regional Diabetes Support Scheme , Sydney Children's Hospital Foundation , Australasian Pediatric Endocrine Care Grant from Pfizer , and for Industry support from Novo Nordisk , Medtronic , Abbott Diagnostics . Publisher Copyright: © 2019 European Cystic Fibrosis Society

PY - 2019/10

Y1 - 2019/10

N2 - Our ability to monitor blood glucose levels has become increasingly accurate over the last few decades. Continuous glucose monitoring (CGM) technology now allows providers and patients the ability to monitor glucose levels retrospectively as well as in real-time for diabetes management. CGM also provides the ability to study glucose patterns and trends for insight into the pathophysiology and natural history of disease. CGM captures a more complete picture of glucose profiles than traditional measures of glycemia such as the hemoglobin A1c or self-monitoring of blood glucose levels. This article provides a review of the history of glucose monitoring, a review of the literature pertaining to CGM with a focus on studies in patients with cystic fibrosis, and discusses practical uses of CGM technology and its application for the evaluation and management of cystic fibrosis related diabetes.

AB - Our ability to monitor blood glucose levels has become increasingly accurate over the last few decades. Continuous glucose monitoring (CGM) technology now allows providers and patients the ability to monitor glucose levels retrospectively as well as in real-time for diabetes management. CGM also provides the ability to study glucose patterns and trends for insight into the pathophysiology and natural history of disease. CGM captures a more complete picture of glucose profiles than traditional measures of glycemia such as the hemoglobin A1c or self-monitoring of blood glucose levels. This article provides a review of the history of glucose monitoring, a review of the literature pertaining to CGM with a focus on studies in patients with cystic fibrosis, and discusses practical uses of CGM technology and its application for the evaluation and management of cystic fibrosis related diabetes.

KW - Artificial pancreas

KW - Continuous glucose monitoring

KW - Cystic fibrosis related diabetes

UR - http://www.scopus.com/inward/record.url?scp=85073663268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073663268&partnerID=8YFLogxK

U2 - 10.1016/j.jcf.2019.08.025

DO - 10.1016/j.jcf.2019.08.025

M3 - Article

C2 - 31679725

AN - SCOPUS:85073663268

SN - 1569-1993

VL - 18

SP - S25-S31

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

ER -

Continuous glucose monitoring in cystic fibrosis – A practical guide

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this